William J Sandborn
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving P, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands B, LUCENT Study Group, Brand S. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2023; 388:2444-2455.
Jun 29, 2023Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Jun 29, 2023N Engl J Med 2023; 388:2444-2455
D'Haens Geert, Dubinsky Marla, Kobayashi Taku, Irving Peter M, Howaldt Stefanie, Pokrotnieks Juris, Krueger Kathryn, Laskowski Janelle, Li Xingyuan, Lissoos Trevor, Milata Joe, Morris Nathan, Arora Vipin, Milch Catherine, Sandborn William J, Sands Bruce E, LUCENT Study Group, Brand Stephan
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus E, Ostad-Saffari E, Scalori A, Oh Y, Tole S, Chai A, Pulley J, Lacey S, Sandborn W, HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021; 7:128-140.
Nov 17, 2021Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Nov 17, 2021Lancet Gastroenterol Hepatol 2021; 7:128-140
Peyrin-Biroulet Laurent, Hart Ailsa, Bossuyt Peter, Long Millie, Allez Matthieu, Juillerat Pascal, Armuzzi Alessandro, Loftus Edward V, Ostad-Saffari Elham, Scalori Astrid, Oh Young S, Tole Swati, Chai Akiko, Pulley Jennifer, Lacey Stuart, Sandborn William J, HICKORY Study Group